Leslie Lauersdorf breaks down what it means to be MRD negative and how she explains MRD negativity to her patients.
As multiple myeloma moves toward being considered a chronic disease, nurses and navigators have new considerations to keep in mind when treating their patients.
Leslie Lauersdorf explains triplet versus quad regimens in relation to multiple myeloma.
Leslie Lauersdorf discusses key considerations for nurses and navigators surrounding the use of CAR T-cell therapy in multiple myeloma.
Leslie Lauersdorf provides an overview of some of the most exciting clinical developments in multiple myeloma based on data presented at ASH 2019.
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
The past week in oncology-related news includes shortages of crucial pediatric cancer drug, results of a study of racial disparities in multiple myeloma, and new drug on the horizon for HER2 metastatic breast cancer.
Darzalex Combination Receives Approval for First-Line Treatment of Patients with Multiple Myeloma Eligible for Transplant
On September 26, 2019, the FDA approved daratumumab (Darzalex; Janssen) in combination with bortezomib, thalidomide, and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem-cell transplant (ASCT). The FDA granted this application priority review.
Elotuzumab, Lenalidomide, and Dexamethasone Combination Demonstrates High Response Rate in High-Risk Smoldering Multiple Myeloma
San Diego, CA—The results of a phase 2 clinical trial presented at ASH 2018 suggest that early therapeutic intervention is beneficial in patients with high-risk smoldering multiple myeloma.
Once-Weekly Carlzomib for Patients with Relapsed or Refractory Survival Multiple Myeloma Improves Progression-Free
In the CHAMPION-1 study, patients with relapsed or refractory multiple myeloma and 1 to 3 previous regimens who received once-weekly carfilzomib had a 77% overall response rate and a median PFS of 12.6 months.
Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma
Multiple myeloma is a cancer of plasma cells in the bone marrow that often leads to bone destruction and bone marrow failure. According to the American Cancer Society, more than 30,280 new cases of multiple myeloma will be diagnosed in 2017, and 12,590 deaths will be attributed to the disease. In the past 20 years, mortality rates associated with multiple myeloma have declined. Novel therapies, as well as improvements in autologous hematopoietic stem-cell transplantation (HSCT) procedures and supportive care, have contributed to extended survival for patients with this malignancy.
Page 1 of 2
Results 1 - 10 of 12
Results 1 - 10 of 12